WHO discussion on the improvement of the quality control of BCG vaccines: Pasteur Institute, Paris, France, 7 June 2005

摘要

The evolution of BCG strains and the diversity of strainsused for production of currently licensed vaccines as well asa need to explore their potential impact on efficacy and safetyof BCG vaccines in humans have been considered at previousWHO meetings, held over the last few years [1,2]. Asrecommended by a WHO working group in December 2004,a meeting to review assays for (1) genetic characterization ofBCG strains and (2) quality control of BCG vaccines, wasconvened at the Institut Pasteur. The meeting was opened byDr. I. Knezevic, Quality Assurance and Safety of Biologicals,World Health Organization, Geneva, who summarizedthe background of the meeting and its objectives in the contextof the revision of WHO requirements for production andcontrol of BCG vaccines [3]. The meeting was hosted by Dr.Gilles Marchal, Reference Laboratory for Mycobacteria ofthe Institut Pasteur. The list of participants is included in theannex of this report.